Skip to main content

Russia, cricket & the fall of Zee-Sony deal

The Economic TimesDaily Newsletter

Wed, Jan 31, 2024 | 05:24 PM IST

Budget2021
Presents
Budget2024
Associations Sponsors
icici DLF
#Budget2024#NewsLive!#NRI#WebStories
Top stories of the day
01
Russia, cricket & everything that led to the fall of Zee-Sony deal Russia, cricket & everything that led to the fall of Zee-Sony deal
Sony and Zee disagreed over more than 20 compliance issues, including the Indian firm's failure to dispose of some Ru...
02 Burman family hikes Religare stake to over 25%; open offer beckons
03 Sensex jumps. It's not just a pre-Budget rally
04 Wipro to lay off hundreds of mid-level employees
05
India's fiscal deficit narrows to 55% of FY24 aim
06 IMF ups India's FY25 growth forecast to 6.5%
07 Core sectors grow at 3.8% in Dec vs 7.9% in Nov
08 Govt mulls tweaks to PLI for textile, pharma
09 FASTag deadline: Is your FASTag KYC incomplete?
NRI reckoner
H-1B visa registration for FY25 to begin on March 6 as US announces a complete overhaul
The United States has introduced a final rule to enhance the integrity of the H-1B visa system. The rule includes a beneficiary-centric selection process, fully electronic registration and petition transmission, and the requirement of valid passport or travel document information for each beneficiary. USCIS now has the authority to deny or revoke H-1B petitions with false attestations or invalid registrations.
ET Career Talks
AI officer is the hot new job that pays over $1 million AI officer is the hot new job that pays over $1 million
Wealth Edition
11
After latest U-turn, Nitish Kumar vows to be in NDA forever and work for the people of Bihar After latest U-turn, Nitish Kumar vows to be in NDA forever and work for the people of Bihar
Bihar Chief Minister Nitish Kumar has confirmed that he will remain in the National Democratic Alliance (NDA) and con...
12 Court allows Hindu side to offer prayers inside Gyanvapi mosque
13 15 expectations of individual taxpayers this Budget
14 The hot new job that pays over $1 million
15 Govt cuts import duty for some mobile parts
16 Tata, Texas, Tower bid for fab lab revamp
17 Zee-Sony Tussle: The test of arbitration law
18 Ashwin retains No. 1 spot in ICC rankings
19 How much an H-1B visa, green card will cost
20 What Bajaj, TVS can do to make EV biz count
WEB STORIES

Brought to you by

Thanks for reading.We'll be back tomorrow with more interesting stories and updates. Follow us on Twitter,Facebook,Youtube and Linkedin.
About us|Advertise with us|Feedback|Sitemap|Code of Ethics
© 2024 Times Internet Limited.
To ensure delivery directly to your inbox, please add newsletter@economictimesnews.com to your address book today.
If you are having trouble viewing this newsletter, please click here
To unsubscribe or edit your subscriptions please click here

Comments

Popular posts from this blog

The first drug for a common, deadly liver disease is here – and more are coming

VIEW IN BROWSER | SUBSCRIBE TUE, MAR 19, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good morning!  Millions of Americans with a common and potentially life-threatening form of liver disease will soon have access to the first-ever treatment for the condition.    In a landmark decision on Thursday, the Food and Drug Administration approved Madrigal Pharmaceuticals ' drug " Rezdiffra ," to be used along with diet and exercise. The company expects the medicine to be available next month with a hefty price tag of $47,400 per year before insurance and other rebates.    So, why is this approval so important?    First of all, people suffering from the disease badly need a treatment. Rezdiffra is specifically approved to treat patients with nonalcoholic steatoh

J&J, Merck and Bristol Myers Squibb are in the hot seat

VIEW IN BROWSER | SUBSCRIBE TUE, JAN 30, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good afternoon! This is Annika Kim Constantino, and I cover the biotech and pharmaceutical industry for CNBC.com .    Three names in the industry – Johnson & Johnson, Merck and Bristol Myers Squibb – face a pivotal few weeks ahead.    CEOs from those companies are slated to testify at a Senate hearing on high prescription drug prices in the U.S. on Feb. 8 at 10 a.m. ET, Sen. Bernie Sanders announced Friday.   It took subpoena threats from the senator, but J&J CEO Joaquin Duato and Merck CEO Robert Davis have agreed to testify after both executives declined earlier requests to appear at the Senate HELP committee's hearing. They join Bristol Myers Squibb CEO Chris Boerner, who agr

How competitive can Roche be in the weight loss drug market?

VIEW IN BROWSER | SUBSCRIBE TUE, SEP 17, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon!  Roche is one of several drugmakers hoping to join the booming weight loss drug market, which Novo Nordisk and Eli Lilly are currently dominating. But can the Swiss company develop drugs that can compete with that duopoly?  The answer isn't clear yet.  We need to see more data from longer and larger clinical trials, which will likely take years for Roche to conduct.  But the company last week presented more early-stage data more early-stage data on its experimental obesity injection and pill, which some analysts said raised concerns about how competitive those products can be if they enter the space. Some analysts said the new results showed that both drugs – which Roche acquired through its nearly $3 billion acquisition of Carmot Therapeutics in December – caused a higher rate of side